• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks

    New Study Shows Complications Rare in Test-tube Fertility Procedures

    Written by Charlotte McLeod
    |
    Jan. 06, 2015 03:54PM PST

    The Associated Press reported that a new American 12-year study shows that complications are rare for women undergoing test-tube fertility procedures. Most frequently problems happen when drugs are used to stimulate ovaries, but even then fatalities don’t usually arise.

    The Associated Press reported that a new American 12-year study shows that complications are rare for women undergoing test-tube fertility procedures. Most frequently problems happen when drugs are used to stimulate ovaries, but even then fatalities don’t usually arise.

    As quoted in the market news:

    Over-stimulated ovaries occurred in 154 out of every 10,000 pregnancy attempts; rates of other complications were less than 10 per 10,000 attempts. There were 58 deaths reported during the 2000-11 study. The study lacks information on their causes, and with more than 1 million pregnancy attempts involved, the results are reassuring, said Dr. Jennifer Kawwass, an Emory University assistant professor and the lead author.

    The study is the first large-scale effort to quantify risks for U.S. patients undergoing these treatments, Kawwass said. Results were published in Tuesday’s Journal of the American Medical Association.

    Click here to read the full report from The Associated Press.

    The Conversation (0)

    Go Deeper

    AI Powered
    Life Science Outlook: World Edition

    Life Science Outlook: World Edition

    Evercore ISI Ranked No. 1 in Extel All-America Research Survey for 4th Straight Year

    Latest News

    Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

    BPH Energy Limited September 2026 Quarter Operations Report

    Quarterly Activities/Appendix 4C Cash Flow Report

    Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

    More News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Life Science Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES